Intravesical Bacillus Calmette-Guerin and Dimethyl Sulfoxide for Treatment of Classic and Nonulcer Interstitial Cystitis:

Peeker, Ralph; Haghsheno, Mohammad-Ali; HOLM??NG, STEN; Fall, Magnus

doi:10.1097/00005392-200012000-00010

Cited by 3 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…| 1679 of pain in classic and non-classic subjects receiving DMSO, as well as a significant decrease in urinary frequency for classic IC. 24 BCG treatment showed no significant difference from baseline measures in any categories. Overall, intravesical DMSO appears to be more effective as compared to BCG in the treatment of IC/BPS.…”

Section: Randomized-controlled Trialsmentioning

confidence: 68%

“…21 Increased urgency and dysuria, lethargy, nausea, fever, and hematuria are also low-frequency adverse effects. 22,23,24 Known sideeffects have been theorized to be related to a transient chemical cystitis that occurs with intravesical DMSO instillation. 25 In contrast, Rossberger and colleagues reported that only 11% of subjects did not experience adverse events.…”

Section: Dmso History and Initial Usementioning

confidence: 99%

“…More contemporary studies have used criteria proposed by the NIDDK. 20,21,23,24,29 Some of the shortcomings in the literature simply reflect the inherent faults in a disease diagnosed by exclusion such as IC/BPS, as well as the nature of the condition which often has a remitting and relapsing course. In patients with cystoscopic or urodynamic abnormalities, subjective responses to DMSO treatment improve, but objective data often show no changes.…”

Section: Limitations Of the Current Literaturementioning

confidence: 99%

See 2 more Smart Citations

Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review

Rawls

Cox

2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

The current evidence backing DMSO is a constellation of cohort studies and a single randomized-controlled trial versus placebo. The optimal dose, dwell time, type of IC most likely to respond to DMSO, definitions of success/failure and the number of treatments are not universally agreed upon. Improvements in study design, phenotyping patients based on symptoms, as well as the emergence of reliable biomarkers of the disease may better guide the use of DMSO in the future.

show abstract

Section: Randomized-controlled Trialsmentioning

confidence: 68%

Section: Dmso History and Initial Usementioning

confidence: 99%

Section: Limitations Of the Current Literaturementioning

confidence: 99%

See 1 more Smart Citation

Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review

Rawls

Cox

2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…Ek et al [17] reported that, among 17 patients with Hunner lesions, DMSO improved pain and urinary frequency in 12 patients but did not improve bladder capacity. Peeker et al [18] reported that while DMSO had no positive effect on maximal functional capacity, it significantly reduced pain and urinary frequency, but only in patients with classic IC (Hunner type IC). Recently, Tomoe [19] reported the effectiveness of maintenance DMSO therapy for 24 months fol-lowing therapeutic hydrodistention in Hunner type IC patients.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study

et al. 2019

View full text Add to dashboard Cite

To evaluate whether hydrodistention with fulguration of Hunner lesions (HD/FUL) plus maintenance dimethyl sulfoxide (DMSO) therapy prolongs the recurrence-free time in patients with Hunner type interstitial cystitis (IC). Methods: The study enrolled patients with Hunner type IC who required repeat HD/FUL due to recurrence of IC symptoms after the first HD/FUL at our institution. All patients received a second HD/FUL plus maintenance DMSO therapy. The maintenance DMSO therapy was performed every 2 weeks for a total of 8 instillations, and then once every 4 weeks thereafter. The recurrencefree time from HD/FUL to therapeutic failure was estimated using the Kaplan-Meier method. The recurrence-free time between the first HD/FUL and second HD/FUL plus maintenance DMSO therapy was statistically compared using the log-rank test. Results: A total of 21 patients (mean age, 66.3 ± 10.8 years) with Hunner type IC were evaluated. The recurrence-free time for the second HD/FUL plus maintenance DMSO therapy was significantly longer than that for the first HD/FUL (P < 0.0001).

show abstract

“…Unfortunately, this was a very small group of patients with little information on other relevant parameters. A recent double-blind, cross-over study compared the efficacy of intravesical BCG to DMSO in 21 patients, 11 with classic and 10 with non-ulcer IC [229]. There was no demonstrable benefit with BCG treatment, while there was a significant urinary frequency decrease with DMSO in classic IC and substantial pain decrease with DMSO in both classic and non-ulcer IC [229].…”

Section: Bacillus Calmette-guerin (Bcg)mentioning

confidence: 99%

New agents for the medical treatment of interstitial cystitis

Theoharides¹,

Sant²

2001

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Interstitial cystitis (IC) is a painful, sterile, disorder of the urinary bladder characterised by urgency, frequency, nocturia and pain. IC occurs primarily in women but also in men with recent findings indicating that chronic, abacterial prostatitis may be a variant of this condition. The prevalence of IC has ranged from about 8 - 60 cases/100,000 female patients depending on the population evaluated. About 10% of patients have severe symptoms that are associated with Hunner's ulcers on bladder biopsy; the rest could be grouped in those with or without bladder inflammation. Symptoms of IC are exacerbated by stress, certain foods and ovulatory hormones. Many patients also experience allergies, irritable bowel syndrome (IBS) and migraines. There have been various reports indicating dysfunction of the bladder glycosaminoglycan (GAG) protective layer and many publications showing a high number of activated bladder mast cells. Increasing evidence suggests that neurogenic inflammation and/or neuropathic pain is a major component of IC pathophysiology. Approved treatments so far include intravesical administration of dimethylsulphoxide (DMSO) or oral pentosanpolysulphate (PPS). New treatments focus on the combined use of drugs that modulate bladder sensory nerve stimulation (neurolytic agents), inhibit neurogenic activation of mast cells, or provide urothelial cytoprotection, together with new drugs with anti-inflammatory activity.

show abstract

Intravesical Bacillus Calmette-Guerin and Dimethyl Sulfoxide for Treatment of Classic and Nonulcer Interstitial Cystitis:

Cited by 3 publications

References 31 publications

Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review

Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review

Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study

New agents for the medical treatment of interstitial cystitis

Contact Info

Product

Resources

About